[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ain Shams University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":557},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,258,0,25,[9,38,67,90,111,138,156,183,204,223,240,270,294,314,340,361,380,406,425,444,465,480,501,519,539],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100054121",false,"NCT07692425","Internal Jugular Vein Collapsibility Index as a Predictor of Hypotension","Internal Jugular Vein Collapsibility Index as a Predictor of Hypotension After The Induction of General Anesthesia in Geriatric Patients Undergoing Laparoscopic Colorectal Surgeries: A Prospective Observational Study","Inclusion Criteria:\n\n* Patients aged ≥ 60 years.\n* Scheduled for elective laparoscopic colorectal surgeries under general anesthesia.\n\nExclusion Criteria:\n\n* Patients' refusal of procedure or participation in the study.\n* Severe aortic stenosis, irregular ventricular rhythm (atrial fibrillation or frequent premature ventricular contractions), or any contraindication to perform passive leg raise (PLR).","ALL","60 Years",{"count":19,"type":20},70,"ESTIMATED","OBSERVATIONAL","The internal jugular vein (IJV) collapsibility index has been proposed as a practical alternative of of the inferior vena cava collapsibility index (IVC-CI), as it is easily accessible using bedside ultrasonography. Several studies have demonstrated a correlation between IJV collapsibility and central venous pressure as well as right atrial pressure.",[24],"Intraoperative Hypotension","NOT_YET_RECRUITING","2026-07-10",{"date":28,"type":29},"2026-07-13","ACTUAL",{"date":31,"type":20},"2026-07-11",{"date":33,"type":20},"2027-02-11",{"name":35,"class":36},"Ain Shams University","OTHER",1,{"id":39,"slug":4,"hasResults":11,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":4,"eligibilityCriteria":43,"healthyVolunteers":11,"sex":16,"minAge":44,"maxAge":17,"enrollmentInfo":45,"targetDuration":4,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":37},"100645143","NCT07678697","Nd:YAG Laser Combined With Injection Sclerotherapy Versus Diode Laser in the Treatment of Reticular Veins and Telangiectasias Using CLaCS Technique","Comparative Study Between Nd:YAG Laser Combined With Injection Sclerotherapy Versus Diode Laser in the Treatment of Reticular Veins and Telangiectasias Using CLaCS Technique","Inclusion Criteria:\n\n* Patients aged 18-60 years.\n* Both sexes.\n* Presence of reticular veins and\u002For telangiectasias (CEAP classification C1).\n* Fitzpatrick skin types II-V.\n* Patients seeking cosmetic treatment.\n\nExclusion Criteria:\n\n* Pregnancy or lactation.\n* History of deep vein thrombosis.\n* Coagulation disorders.\n* Allergy to sclerosant agents.\n* Active skin infection at treatment site.\n* Previous treatment of target veins within 6 months.\n* Great saphenous vein or short saphenous vein incompetence.\n* Deep venous insufficiency or thrombosis.\n* Abnormal venous duplex findings.","18 Years",{"count":46,"type":20},80,"INTERVENTIONAL",[49],"NA","This study aims to compare the efficacy (in terms of vein clearance) and safety of Nd:YAG laser combined with injection sclerotherapy versus diode laser combined with injection sclerotherapy in the treatment of reticular veins and telangiectasias using the Cryo-Laser and Cryo-Sclerotherapy (CLaCS) technique.",[52,53,54,55,56,57],"Nd:YAG Laser","Sclerotherapy","Diode Laser","Reticular Veins","Telangiectasias","CLaCS Technique","RECRUITING","2026-06-25",{"date":61,"type":29},"2026-07-01",{"date":63,"type":29},"2026-06-01",{"date":65,"type":20},"2026-12-01",{"name":35,"class":36},{"id":68,"slug":4,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":47,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":37},"100632755","NCT07517809","Comparison Between Ultrasound-Guided Costoclavicular and Lateral-Sagittal Infraclavicular Brachial Plexus Blocks in Adult Distal Upper Limb Surgeries","Comparison Between Ultrasound-Guided Costoclavicular and Lateral-Sagittal Infraclavicular Brachial Plexus Blocks in Adult Distal Upper Limb Surgeries : A Randomized Controlled Trial","Inclusion Criteria:\n\n* ASA physical status I-III\n* Distal upper limb surgery requiring brachial plexus block.\n* Patient approval after written and informed consent to participate.\n\nExclusion Criteria:\n\n* Patient refusal.\n* Allergy to drugs used.\n* Infection at puncture site.\n* Coagulopathy or anticoagulant therapy.\n* Pre-existing neuropathy or neurological deficit in the affected limb.\n* Severe pulmonary disease.\n* BMI \\> 40 kg\u002Fm².","21 Years","65 Years",{"count":76,"type":20},50,[49],"The aim of the study is to compare the onset time of the costoclavicular approach of brachial plexus block with that of the lateral-sagittal infraclavicular approach in adults distal upper limb surgeries.",[80,81],"Regional Anesthesia Block","Brachial Plexus Blocks","2026-06-22",{"date":84,"type":29},"2026-06-24",{"date":86,"type":29},"2026-02-16",{"date":88,"type":20},"2026-09",{"name":35,"class":36},{"id":91,"slug":4,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":16,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":47,"phases":99,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":37},"100644067","NCT07669012","a Comparive Study of Ketamine-Propofol Versus Dexmedetomidine-Propofol Sedation in Pediatric Patients Undergoing Cardiac Catheterization for Device Closure of Simple Left-to-right Shunts","Inclusion Criteria:\n\n* Age 2-12 years, male or female\n* Weight ≥ 10 kg\n* Scheduled for elective transcatheter device closure of a simple left-to-right shunt, including:\n* Secundum atrial septal defect (ASD) suitable for device closure\n* Small muscular ventricular septal defect (VSD) eligible for percutaneous device closure\n* Patent ductus arteriosus (PDA) closure\n* Procedure performed with transthoracic or transesophageal echocardiographic guidance according to the cardiology team's practice\n* ASA physical status II-III\n* Written informed consent obtained from a parent or legal guardian\n\nExclusion Criteria:\n\n* Cyanotic congenital heart disease\n* Complex congenital cardiac lesions\n* Risk of pulmonary hypertensive crisis\n* Requirement for general anesthesia and cuffed endotracheal tube at the discretion of the cardiology or anesthesia team\n* Baseline oxygen requirement \\> 2 L\u002Fmin\n* Use of noninvasive ventilation\n* Known allergy or intolerance to ketamine, dexmedetomidine, or propofol\n* Significant hepatic impairment\n* Significant renal impairment\n* Advanced atrioventricular block\n* Clinically significant bradyarrhythmia\n* Uncontrolled epilepsy\n* Raised intracranial pressure\n* Severe obstructive sleep apnea\n* Craniofacial anomalies associated with anticipated difficult airway management\n* BMI \\> 97th percentile when judged to confer high risk of sedation-related airway obstruction\n* Current beta-blocker use\n* Current clonidine use\n* Acute upper respiratory tract infection within 2 weeks before the procedure\n* Emergency or add-on procedures\n* Anticipated procedure duration \\\u003C 20 minutes\n* Anticipated procedure duration \\> 3 hours","2 Years","12 Years",{"count":98,"type":20},124,[100],"PHASE1","This study aims To compare the safety and efficacy of ketamine-propofol versus dexmedetomidine-propofol sedation in pediatric patients undergoing cardiac catheterization for device closure of simple left-to-right shunts",[103],"Sedation and Analgesia","2026-06-20",{"date":59,"type":29},{"date":107,"type":29},"2025-10-22",{"date":109,"type":20},"2027-02-15",{"name":35,"class":36},{"id":112,"slug":4,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":117,"maxAge":74,"enrollmentInfo":118,"targetDuration":4,"studyType":47,"phases":119,"briefSummary":121,"conditions":122,"keywords":126,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":37},"100644346","NCT07663435","Influence of Superficial Parasternal Intercostal Plane Block on Internal Thoracic Artery Caliber to Facilitate Surgical Harvesting in CABG","IMA CABG PIPB","Inclusion Criteria:\n\n* • Age group: Adult patients from age of 22 to 65 years.\n\n  * Sex: Both sexes\n  * Patients undergoing CABG with IMA harvesting\n\nExclusion Criteria:\n\n* • Patients with pre-existing active bloodstream infection or systemic infection\n\n  * Refuse consent\n  * IMA graft not suitable\n  * Morbidly obese (BMI \\> 40 )\n  * Hemodynamic instability\n  * Severe pulmonary disease\n  * Previous thoracic surgeries (makes it difficult to harvest IMA)\n  * Advanced malignancy or chronic disease with life expectancy less than six months\n  * Emergency surgery","22 Years",{"count":76,"type":20},[120],"PHASE3","Influence of Superficial Parasternal Intercostal Plane Block (SPIPB) on Internal Thoracic Artery (ITA) Caliber and Surgical Harvesting Efficiency in Coronary Artery Bypass Grafting (CABG)",[123,124,125],"Pain Management","Parasternal Block","CABG Graft Integrity",[127,128,129],"IMA","CABG","SPIPB","2026-06-17",{"date":132,"type":29},"2026-06-23",{"date":134,"type":20},"2026-07",{"date":136,"type":20},"2026-12-31",{"name":35,"class":36},{"id":139,"slug":4,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":143,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":150,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":37},"100641519","NCT07623330","Use of TEE Derived Measurement vs Direct Measurement Under General Anesthesia in Assessment of Pressure Gradient in Peri Membranous Ventricular Septal Defect","Inclusion Criteria:\n\n* Pediatric patients (6 months to 5 years).\n* Patients with isolated peri-membranous VSD.\n* Scheduled for surgical VSD closure.\n\nExclusion Criteria:\n\n* Refusal of legal guardians.\n* Patients with other types of VSD.\n* Patients with pulmonary vascular diseases.\n* Patients with unrestrictive VSD.\n* Recent or active upper respiratory tract infection.\n* Any relative or absolute contraindication for TEE.","6 Months","5 Years",{"count":146,"type":20},115,"In this study, the investigators aim to compare the pressure gradient obtained by transesophageal echocardiography across the restrictive peri membranous VSD with direct catheter-based measurements of such gradient.",[149],"Peri Membranous Ventricular Septal Defect",{"date":82,"type":29},{"date":152,"type":20},"2026-05-27",{"date":154,"type":20},"2027-04-20",{"name":35,"class":36},{"id":157,"slug":4,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":44,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":47,"phases":164,"briefSummary":166,"conditions":167,"keywords":169,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":180,"leadSponsor":182,"locationsCount":37},"100641525","NCT07655791","Efficacy and Safety of Oral Nicotinamide as an Adjunctive Therapy in Patients With Sepsis","Evaluation of the Efficacy and Safety of Oral Nicotinamide as an Adjunctive Therapy in Patients With Sepsis","Inclusion Criteria:\n\n* Patients older than 18 years of any gender who were admitted to the intensive care unit\n* Diagnosed as sepsis patient with the Sequential Organ Failure Assessment (SOFA) Score described as an Increase in SOFA score ≥2 points due to infection.\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* Patients who had already been taking antioxidant supplements before recruiting.\n* Patient with contraindications or reported allergies to Nicotinamide.",{"count":163,"type":20},60,[165],"PHASE4","Sepsis is a severe, life-threatening condition caused by an abnormal host response to infection, which includes systemic inflammation, oxidative stress, and increasing organ dysfunction. It is frequently associated with bacterial, viral, fungal, or parasite infections, as well as non-infectious illnesses like trauma and pancreatitis. It remains a primary cause of mortality in hospitals, with rates nearing 40% in severely ill patients. pathophysiological, excessive cytokine release (e.g., TNFα, IL-6, IL-1β) and reactive oxygen\u002Fnitrogen species lead to mitochondrial injury, immunosuppression, and multiple organ failure. Sepsis diagnosis is guided byNEWS2 \\& a SOFA score ≥2, hypotension, and elevated lactate, while worsening SOFA scores predict poor outcomes. Standard management focusses on early antibiotic therapy, fluid resuscitation, and vasoactive support. Standard anti-inflammatory methods using steroidal or non-steroidal medicines may show little efficacy to improve the patient's clinical outcomes. Adjunctive antioxidant therapies, including vitamins C and E, NAC, and melatonin, have demonstrated reductions in oxidative stress and organ dysfunction. Nicotinamide (NAM) (vitamin B3), a precursor of NAD+\u002FNADP+ critical for energy metabolism and cellular repair, has emerged as a potential therapeutic candidate due to its ability to attenuate cytokine production, modulate immune responses, and mitigate oxidative damage. Usual dose of NAM (500mg-1500mg per day) is generally safe. A dose of 1000 mg was found to be safe and effective in reducing the circulating inflammatory cytokines showing a good profile as an anti-inflammatory adjunct therapy. Higher than usual NAM dose can increase the likelihood of adverse effects, such as diarrhea, increased liver enzymes (rarely occurring at doses exceeding 3 grams per day), symptoms of thrombocytopenia (including increased bruising and bleeding), and stomach upset.\n\nSince the role of NAM as adjunct therapy in sepsis management is not yet established, further large-scale clinical studies are recommended to establish its efficacy and safety in sepsis management.\n\nThe aim of our study is to evaluate the efficacy and safety of the addition of Nicotinamide (1000mg oral tablet) as an adjunct therapy to improve the outcome of septic patients.",[168],"Sepsis - to Reduce Mortality in the Intensive Care Unit",[170,171,172,173,174,175],"Sepsis","IL-6","NF-kB","anti-inflammatory","Nicotinamide","Mortality","2026-06-13",{"date":178,"type":29},"2026-06-18",{"date":61,"type":20},{"date":181,"type":20},"2027-01-01",{"name":35,"class":36},{"id":184,"slug":4,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":16,"minAge":44,"maxAge":74,"enrollmentInfo":189,"targetDuration":4,"studyType":47,"phases":190,"briefSummary":191,"conditions":192,"keywords":194,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":37},"100641649","NCT07609810","Palmitoylethanolamide in Ulcerative Colitis","The Effect of Palmitoylethanolamide on the Clinical Outcomes in Ulcerative Colitis Patients","Inclusion Criteria:\n\n* Confirmed diagnosis of ulcerative colitis (UC) by established clinical and endoscopic criteria.\n* Active mild-to-moderate UC patients defined by a SCCAI score ≥ 5 and \\\u003C 12 at screening, not responding to 5-aminosalicylates (5-ASA) defined as persistent rectal bleeding beyond 2 weeks or failure to achieve sustained symptom relief after 40 days of appropriate 5-ASA therapy, steroid-dependent defined as unable to reduce steroids below the equivalent of prednisolone 10 mg\u002Fday or budesonide below 3 mg\u002Fday within 3 months of starting steroids, without recurrent active disease or who have a relapse within 3 months of stopping steroids and they currently take azathioprine.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding.\n* Alcohol or drug abuse.\n* Allergy or known hypersensitivity to palmitoylethanolamide.\n* Active infection (enteric or systemic).\n* Uncontrolled metabolic\u002F neurologic conditions: uncontrolled hypertension, uncontrolled diabetes, migraine disorders or other uncontrolled neurologic disease.\n* Other autoimmune diseases.\n* Severe or acute severe colitis requiring hospitalization.\n* UC patients requiring colectomy.\n* Crohn disease (CD), chronic pancreatitis, cholecystitis or other inflammatory conditions involving the gastrointestinal tract (GIT).\n* Patients with renal or liver disease.\n* Patients who have never been treated for UC.\n* Any patients on biologics.\n* Patients using NSAIDs or aspirin (due to interference with fecal calprotectin results).",{"count":163,"type":20},[49],"Evaluate the effects of PEA supplementation on disease activity, health-related quality of life (HRQoL) and inflammatory biomarkers in patients with active mild-to-moderate UC.",[193],"Ulcerative Colitis (UC)",[195],"palmitoylethanolamide - endocannabinoid - disease activity","2026-06-12",{"date":198,"type":29},"2026-06-16",{"date":200,"type":20},"2026-07-15",{"date":202,"type":20},"2029-02-15",{"name":35,"class":36},{"id":205,"slug":4,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":16,"minAge":73,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":47,"phases":212,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":37},"100578984","NCT06818396","Analgesic Efficacy of Fascia Iliaca Compartment Block Compared With Intrathecal Nalbuphine for Hip Surgery Under Spinal Anesthesia","Analgesic Efficacy of Fascia Iliaca Compartment Block Compared With Intrathecal Nalbuphine for Hip Surgery Under Spinal Anesthesia: a Randomized Controlled Trial","Inclusion Criteria:\n\n* American Society of Anesthesiologists (ASA) score (ASA I- ASA II).\n* Age ≥ 21years.\n* Body mass index \\\u003C 35 kg\u002Fm2\n\nExclusion Criteria:\n\n* Patient's refusal.\n* Known coagulopathy.\n* Known peripheral neuropathy or neurological deficits.\n* Known allergy to study drugs",{"count":211,"type":20},120,[49],"It is already known that fascia iliaca compartment block and intrathecal nalbuphine are very effective ways in postoperative pain control in patients having hip surgeries.",[215],"Postoperative Pain",{"date":217,"type":29},"2026-06-15",{"date":219,"type":29},"2025-02-18",{"date":221,"type":20},"2026-10-31",{"name":35,"class":36},{"id":224,"slug":4,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":16,"minAge":73,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":47,"phases":230,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":234,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":37},"100523217","NCT06092749","Chronic Unilateral Lumbar Radicular Pain","Effectiveness of Transgrade vs Interlaminar Epidural Steroid Injection for Chronic Unilateral Lumbar Radicular Pain","Inclusion Criteria:\n\n* \\> 6-month history of persistent pain in one leg with back pain.\n* Capable of giving informed consent.\n* Unsatisfactory response to conventional treatments including physical therapy or medications with a numeric rating scale (NRS) ≥ 5.\n\nExclusion Criteria:\n\n* Previous lumbar spinal surgery.\n* Myelopathy.\n* Rheumatoid disorders.\n* Psychiatric disorders\n* Bleeding or coagulation disorders",{"count":46,"type":20},[49],"Chronic neuropathic lumbar pain is among one of the most widespread complaints of patients.Many approaches have been attempted to target chronic pain, with varying efficacy and risks. Transgrade (TG) epidural injection is a new technique using a Racz- Coudé needle for epidural access at a \"transgrade\" angle without requiring any specialized hardware or accessories. Interlaminar (IL) epidural steroid injection (ESI) is one of the procedures that involves the delivery of injectate to the epidural space through directing a needle between the laminae of two adjacent vertebrae.",[233],"Neuropathic Pain",{"date":217,"type":29},{"date":236,"type":29},"2023-11-01",{"date":238,"type":20},"2026-07-31",{"name":35,"class":36},{"id":241,"slug":4,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":247,"sex":16,"minAge":73,"maxAge":248,"enrollmentInfo":249,"targetDuration":4,"studyType":47,"phases":250,"briefSummary":251,"conditions":252,"keywords":258,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":266,"completionDateStruct":267,"leadSponsor":269,"locationsCount":37},"100642888","NCT07641933","Biological, Radiographic and Clinical Evaluation of Various Inter-Visit Root Canal Dressings in Retreatment Cases","Biological, Radiographic and Clinical Evaluation of Various Inter-Visit Root Canal Dressings in Retreatment Cases: A Randomized Controlled Clinical Trial","RCT","Inclusion Criteria:\n\n1. Age: 21-45 years.\n2. Medically free patients. (ASA Class 1)\n3. Gender: males and females\n4. Patients who are cooperative at operation and in attendance at scheduled follow-up visits.\n5. Restorable root canal treated permanent lower first molars with periapical lesions.\n6. Small (\\\u003C5 mm) or medium periapical lesion size (5-10 mm)\n\nExclusion Criteria:\n\n1. Patients with a history of allergic reactions to any of the study materials.\n2. Teeth that become non-restorable after complete caries excavation.\n3. Teeth that have mobility or deep periodontal pockets.\n4. Teeth with internal or external resorption.",true,"45 Years",{"count":163,"type":20},[100],"The aim of this clinical trial is to evaluate anti-inflammatory effect of various intracanal medications:\n\n1. Calcium Hydroxide Slurry mixed with 3% Sodium Hypochlorite\n2. Calcium Silicate\n3. Calcium Hydroxide\n\nIn retreatment cases in terms of:\n\n1. Biological Evaluation: Biomarker (IL 1B)\n2. Radiographic Evaluation: CBCT\n3. Clinical Evaluation: Pain Score (VAS)",[253,254,255,256,257],"Intervention Studies","ASA Physical Status I","Intracanal Medication","Periapical Abscess","Retreatment",[259,260,261,262,263],"intracanal medication","retreatment","inflammatory marker","radiographic","pain score","2026-06-10",{"date":196,"type":29},{"date":63,"type":29},{"date":268,"type":20},"2027-08",{"name":35,"class":36},{"id":271,"slug":4,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":275,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":16,"minAge":44,"maxAge":4,"enrollmentInfo":277,"targetDuration":4,"studyType":47,"phases":278,"briefSummary":279,"conditions":280,"keywords":283,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":37},"100615978","NCT07299630","Blocking Sphenopalatine Ganglion by Intranasal Lidocaine Spray in Partial Turbinectomy Surgeries","Efficacy of Intranasal Sphenopalatine Ganglion Block by Lidocaine Spray for Partial Turbinectomy Surgeries","SPG block","Inclusion Criteria:\n\n* Undergoing elective partial turbinectomy surgery\n* Age 18 years or older\n\nExclusion Criteria:\n\n* Patient refusal\n* Kidney or liver impairment\n* Pregnant or breast-feeding women\n* Allergy to any of the drugs used in the study\n* OR time more than 90 minutes (defined as time after anaesthesia induction and securing Endotracheal tube to end of surgery, excluding extubation time)",{"count":76,"type":20},[120],"Nasal turbinectomy surgeries are usually done as day case surgeries as most patients are young with unremarkable comorbidities. However, considerations are still present towards patients of old age or those suffering from obesity or obstructive sleep apnea (OSA). Different techniques are still evolving to improve handling those patients to decrease complications, enhance recovery after surgery and increase patient satisfaction. Targeting sphenopalatine ganglion block by topical local anesthesia is a proposed technique that could help by decreasing peri-operative opioid consumption.",[281,282],"Turbinate Surgery","Sphenopalatine Block",[275,284,285],"lidocaine spray","partial turbinectomy surgery","2026-06-07",{"date":288,"type":29},"2026-06-09",{"date":290,"type":29},"2025-12-20",{"date":292,"type":20},"2026-06-30",{"name":35,"class":36},{"id":295,"slug":4,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":247,"sex":16,"minAge":73,"maxAge":17,"enrollmentInfo":300,"targetDuration":4,"studyType":47,"phases":302,"briefSummary":303,"conditions":304,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":311,"leadSponsor":313,"locationsCount":4},"100643660","NCT07633834","Evaluation of Corrective Surgery Versus Dental Implants in Compromised Mandibular Molars","Clinical and Radiographic Outcomes of Corrective Surgery Versus Dental Implant Treatment for Management of Compromised Permanent Mandibular Molars (An In-vivo Study)","Inclusion Criteria:\n\n* Good oral hygiene and motivation for follow-up care.\n* Ability to understand and sign informed consent.\n* Localized Root\u002FPeriodontal Disease: Severe attachment loss or bone loss (e.g., severe localized periodontitis) affecting the mesial root, while the other root remains healthy.\n* Furcation Involvement: Class II or III furcation involvements where the disease cannot be treated by conventional methods.\n* Vertical root fracture confined to the mesial root.\n* Non-treatable perforation in the mesial root.\n* Extensive sub-gingival root caries affecting the mesial root.\n* Extensive un-treatable internal and external root resorption related to the mesial root.\n\nExclusion Criteria:\n\n* Uncontrolled systemic diseases (e.g., diabetes mellitus, bleeding disorders, immunosuppression).\n* Fused or poorly shaped roots,\n* Active periodontal or endodontic infection at adjacent teeth that may interfere with treatment outcomes.\n* Severe bruxism or occlusal parafunction.\n* History of radiation therapy in the head and neck region.\n* Pregnancy or lactation.\n* Poor compliance or inability to attend follow-up visits.\n* Smoking more than 10 cigarettes per day.",{"count":301,"type":20},28,[49],"This study seeks to assess the clinical, radiographic, and patient-reported outcomes of hemisection versus implant over a 12 months period, generating robust evidence to guide clinical decision-making and enhance patient care.",[305,306],"Root Caries","Vertical Root Fracture","2026-06-05",{"date":309,"type":29},"2026-06-08",{"date":181,"type":20},{"date":312,"type":20},"2028-01-01",{"name":35,"class":36},{"id":315,"slug":4,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":47,"phases":321,"briefSummary":322,"conditions":323,"keywords":329,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":339,"locationsCount":37},"100643696","NCT07633457","Comparison Between Outcomes of Closure of Idiopathic Macular Hole Using Autologus Tenon Capsule Graft and Internal Limiting Membrane Flap Techniques (Pilot Study)","Inclusion Criteria:\n\n* Patients diagnosed with idiopathic full-thickness macular hole\n* ≥400 µm in horizontal diameter\n\nExclusion Criteria:\n\n* Media opacity preventing adequate OCT\u002FOCTA imaging\n* Other retinal vascular pathology as retinal vascular occlusion\n* Intraoperative complications\n* Signal noise ratio using OCTA \\\u003C6\\\\10\n* Poor fixation of the patient",{"count":320,"type":20},20,[49],"The aim of this study is to compare the functional visual outcomes, anatomical closure rate and macular perfusion changes assessed by OCT and OCTA after surgical repair of macular hole using Tenon capsule graft versus ILM flap.",[324,325,326,327,328],"Macular Hole Surgery","ILM Peeling","Tenon Capsule","ILM Flap","Macular Hole",[330,331,332,333],"Macular hole","ILM flap","Tenon capsule","Graft","2026-06-04",{"date":309,"type":29},{"date":337,"type":29},"2025-11-09",{"date":312,"type":20},{"name":35,"class":36},{"id":341,"slug":4,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":11,"sex":16,"minAge":44,"maxAge":346,"enrollmentInfo":347,"targetDuration":4,"studyType":47,"phases":349,"briefSummary":350,"conditions":351,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":360},"100643679","NCT07634991","To Evaluate the Efficacy and Safety of N-acetyl Cysteine Administration in Patients With Diabetic Retinopathy","Effect of N-Acetyl Cysteine on Oxidative Stress and Clinical Outcome of Patients With Diabetic Retinopathy","Inclusion Criteria:\n\n* Patients with type 2 diabetes mellitus\n\n  * Patients with mild to moderate degrees of diabetic retinopathy\n  * Patients over the age of 18 and under the age of 70 years\n  * Patients who voluntarily give their informed consent\n  * HbA1C (glycosylated hemoglobin) less than 10%\n  * FBG less than 240 mg\u002Fdl\n  * Body mass index (BMI) less than 40 kg\u002Fm2\n\nExclusion Criteria:\n\n* • Patients with any other ophthalmologic conditions than diabetic retinopathy\n\n  * Patients with previous surgical or laser treatment\n  * Pregnant or breastfeeding patients\n  * Patients using antioxidants.\n  * Systemic anti-VEGF or pro-VEGF treatment within 4 months before randomization\n  * Patients who are currently participating in other clinical trials\n  * Severe liver or renal disease, (AST or ALT \\>3 times ULN or Total bilirubin \\>3 times ULN), (CrCl\\\u003C 60 ml\u002Fmin)\n  * Current history of drug or alcohol abuse Malignancies","70 Years",{"count":348,"type":20},76,[165],"N-acetylcysteine (NAC) emerges as a crucial factor in mitigating oxidative stress and inhibiting vascular endothelial activation in diabetic patients, through its effect on VEGF expression as VEGF is involved in the development of diabetic microvascular complications through the promotion of retinal angiogenesis and increased vascular permeability.\n\nIt was reported in the literature that NAC administration was safe in several studies. It was shown that the dose of 1200 mg is safe and effective.\n\nTo the best of our knowledge, the present study is the first to be designed to evaluate the effect of N-acetyl cysteine on diabetic retinopathy in type 2 diabetic patients.",[352],"Diabetic Retinopathy (DR)","2026-06-03",{"date":288,"type":29},{"date":356,"type":29},"2026-01-10",{"date":358,"type":20},"2026-12-30",{"name":35,"class":36},2,{"id":362,"slug":4,"hasResults":11,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":4,"eligibilityCriteria":366,"healthyVolunteers":11,"sex":16,"minAge":44,"maxAge":4,"enrollmentInfo":367,"targetDuration":369,"studyType":21,"phases":4,"briefSummary":370,"conditions":371,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":37},"100639527","NCT07630662","Effectiveness of Diaphragmatic Function and Parasternal Intercostal Muscles Functions as Predictors for Successful Weaning From Mechanical Ventilation","Ultrasound Evaluation of Diaphragmatic Functions and Parasternal Intercostal Muscle Thickening Fraction as Predictors of Successful Weaning From Mechanical Ventilation.","Inclusion Criteria:\n\n* 1\\. Adult patients more than 18 years old. 2. Patient on mechanical ventilation more than 48 hours.\n\nExclusion Criteria:\n\n* 1\\. Declining to give a written informed consent. 2. Diaphragmatic paralysis or injury",{"count":368,"type":20},77,"2 Days","Critically ill patients frequently develop respiratory muscle dysfunction that may contribute to difficult and prolonged weaning from mechanical ventilation. that is besides complications such as barotrauma, ventilator-acquired pneumonia, accumulation of secretions, and lung atelectasis.\n\nThe ultrasound estimation of parasternal intercostal muscle and diaphragmatic functions is a method to evaluate if there is a good chance of weaning outcomes.",[372],"Ventilated Patient in Intensive Care","2026-06-02",{"date":307,"type":29},{"date":376,"type":29},"2026-01-01",{"date":378,"type":20},"2026-08-01",{"name":35,"class":36},{"id":381,"slug":4,"hasResults":11,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":4,"eligibilityCriteria":385,"healthyVolunteers":247,"sex":16,"minAge":73,"maxAge":386,"enrollmentInfo":387,"targetDuration":4,"studyType":47,"phases":389,"briefSummary":390,"conditions":391,"keywords":393,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":37},"100638340","NCT07627633","Efficacy of Adjunctive Theravex Tissue Care® With Xenograft in Internal Sinus Lifting","Efficacy of Adjunctive Theravex Tissue Care® With Xenograft Using Osseodensification in Internal Sinus Lifting: a Randomized Controlled Clinical Study","Inclusion Criteria:\n\n* Patient partially edentulous with maxillary posterior edentulous ridge after extraction of more than 4 months.\n* Both genders will be selected males and females.\n* Adult patients aged between 21 and 50 years of age.\n* Good general health (American Society of Anesthesiology Physical Status I-II).\n* Initial residual alveolar ridge height ranging between 4 to 6 mm according to preoperative CBCT.\n* No previous surgery or radiation treatment on the maxillary sinus\n\nExclusion Criteria:\n\n* Smokers\n* Pregnant and lactating females.\n* Poor oral hygiene (Full-Mouth Plaque Score (FMPS) \\> 20%).\n* Patients with occlusal or malalignment problems.\n* Patients with parafunctional habits.\n* Presence of acute or chronic sinus pathoses or sinus membrane perforation.","50 Years",{"count":388,"type":20},16,[49],"The purpose of this clinical study is to evaluate the clinical and radiographic efficacy of Theravex Tissue Care Plus (Bone Bioactive Liquid) as an adjunct to a xenograft in crestal maxillary sinus elevation with simultaneous implant placement using the osseodensification technique. The study will enroll 16 partially edentulous patients who have inadequate posterior maxillary bone height. Participants will randomly undergo the sinus elevation and implant placement utilizing either a xenograft alone or a mixture of the xenograft and Theravex. The main question the study aims to answer is whether the adjunctive use of Theravex with a xenograft enhances vertical bone gain, bone density, and implant stability compared to using a xenograft alone.",[392],"Internal Sinus Lifting",[394,395,392,396,397,398],"Bone Bioactive Liquid","Theravex Tissue Care","Implant","Xenograft","Sinus augmentation","2026-05-30",{"date":334,"type":29},{"date":402,"type":20},"2026-10-01",{"date":404,"type":20},"2029-05-01",{"name":35,"class":36},{"id":407,"slug":4,"hasResults":11,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":11,"sex":16,"minAge":44,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":413,"conditions":414,"keywords":416,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":424,"locationsCount":37},"100632321","NCT07512167","Tetanus Severity Score for Prediction of Mortality in Manifest Tetanus","Comparison of Three Scoring Systems for Prediction of Mortality in Patients Admitted to the Intensive Care Unit With Manifest Tetanus","Inclusion criteria:\n\n* Adults (age 18 years old or more).\n* Any sex (male or female), regardless of gender identity.\n* Diagnosis of manifest tetanus according to the WHO criteria (https:\u002F\u002Fwww.who.int\u002Fnews-room\u002Ffact-sheets\u002Fdetail\u002Ftetanus), that is the presence of one or both of the following criteria with or without the history of specific wound or injury:\n\n  * Sustained spasm of the facial muscles in which person appears grinning.\n  * Painful muscular contractions\n\nExclusion criteria:\n\n* Age \\\u003C 18 years.\n* Absent criteria of manifest tetanus, as per the WHO criteria (https:\u002F\u002Fwww.who.int\u002Fnews-room\u002Ffact-sheets\u002Fdetail\u002Ftetanus).\n* Incomplete medical record with missing data required to calculate the Tetanus Severity Score, Philips Score, or Dakar score.\n* Incomplete medical record with missing data regarding the primary outcome measure (survival to hospital discharge or in-hospital mortality).",{"count":146,"type":20},"Three scoring systems will be applied to patients suffering from manifest tetanus and will be related to mortality.",[415],"Tetanus, Manifest",[417],"Tetanus, Tetanus Severity Score","2026-05-26",{"date":420,"type":29},"2026-05-28",{"date":422,"type":29},"2026-04-15",{"date":217,"type":20},{"name":35,"class":36},{"id":426,"slug":4,"hasResults":11,"nctId":427,"briefTitle":428,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":11,"sex":430,"minAge":431,"maxAge":17,"enrollmentInfo":432,"targetDuration":4,"studyType":47,"phases":434,"briefSummary":435,"conditions":436,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":443,"locationsCount":37},"100639810","NCT07610070","Comparative Study Between Ultrasound Guided Paravertebral Plane Block and Erector Spinae Plane Block on Post-operative Analgesia After Total Abdominal Hysterectomy","Inclusion Criteria:\n\n* ASA I and ASA II patients.\n* Female, 30-60 years of age.\n* Scheduled for total abdominal hysterectomy.\n\nExclusion criteria:\n\n* Patient refusal of procedure or participation in the study.\n* Opioid or analgesic abuse.\n* Known allergy to study drug.\n* Any contraindication of regional anesthesia including:\n* Local infection at the site of puncture.\n* Having history of hematological disorders, including coagulation abnormality.","FEMALE","30 Years",{"count":433,"type":20},48,[49],"The intent of this study is to compare the efficacy of the erector spinae plane block (ESPB) and paravertebral plane block in reducing postoperative opioid consumption and pain in patients with total abdominal hysterectomy.",[437],"Post Operative Analgesia","2026-05-22",{"date":152,"type":29},{"date":441,"type":20},"2026-05-10",{"date":154,"type":20},{"name":35,"class":36},{"id":445,"slug":4,"hasResults":11,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":11,"sex":16,"minAge":450,"maxAge":451,"enrollmentInfo":452,"targetDuration":4,"studyType":47,"phases":454,"briefSummary":455,"conditions":456,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":4},"100638484","NCT07609836","Caudal Dexamethasone - Bupivacaine in Neonates","Analgesic Efficacy Of Dexamethasone As Adjuvant To Caudal Bupivacaine For Neonates Undergoing Inguinal Hernia Repair: Randomized Controlled Study","Inclusion Criteria:\n\n* full term neonate\n* ASA I \\& ASA II\n* Scheduled for inguinal hernia repair\n\nExclusion Criteria:\n\n* Patients with allergies to studied drugs\n* body weight \\\u003C3 kilograms\n* parents refusal","1 Day","28 Days",{"count":453,"type":20},150,[49],"Randomied controlled study Evaluate the effects of caudal Dexamethasone in neonates",[457],"We Are Studying the Effects of Caudal Dexamethasone in Neonates Undergoing Inguinal Hernia Repair","2026-05-20",{"date":152,"type":29},{"date":461,"type":20},"2026-05",{"date":463,"type":20},"2026-12",{"name":35,"class":36},{"id":466,"slug":4,"hasResults":11,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":247,"sex":16,"minAge":73,"maxAge":17,"enrollmentInfo":471,"targetDuration":4,"studyType":47,"phases":472,"briefSummary":473,"conditions":474,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":476,"startDateStruct":477,"completionDateStruct":478,"leadSponsor":479,"locationsCount":4},"100640948","NCT07608497","Evaluation of Corrective Surgery Versus Dental Implants in Compromised Upper Molars","Clinical and Radiographic Outcomes of Corrective Surgery Versus Dental Implant Treatment for Management of Compromised Permanent Maxillary Molars (An In-Vivo Study)","Inclusion Criteria:\n\n* Patients will be illegible for root amputation if they one or more of the following criteria:\n* Severe vertical bone loss affecting only Mesio-buccal root of Maxillary molar.\n* Through-and-through furcation involvement\n* Vertical root fracture confined to a Mesio-buccal root of Maxillary molar.\n* Extensive root caries affecting Mesio-buccal root of Maxillary molar.\n* Endodontic failure or non- treatable perforation in Mesio-buccal root of Maxillary molar\n* Extensive internal or external non- treatable root resorption related to Mesio-buccal root of Maxillary molar.\n* Patients who do not meet the above criteria and present with Maxillary molars in more severely compromised conditions will be directed for extraction followed by dental implant placement.\n\nExclusion Criteria:\n\n* \\- Uncontrolled systemic disease, immunosuppression, recent bisphosphonate use, head and neck radiotherapy.\n* Patient non-compliance or poor oral hygiene.\n* Heavy smoking or inability to commit to maintenance.\n* Root anatomy or interradicular bone that precludes predictable root amputation; insufficient bone for implant placement that cannot be reasonably augmented.",{"count":301,"type":20},[49],"This study seeks to assess the clinical, radiographic, and patient-reported outcomes of root amputation versus implant over a 12 months period, generating robust evidence to guide clinical decision-making and enhance patient care.",[305],"2026-05-19",{"date":152,"type":29},{"date":181,"type":20},{"date":312,"type":20},{"name":35,"class":36},{"id":481,"slug":4,"hasResults":11,"nctId":482,"briefTitle":483,"officialTitle":484,"acronym":4,"eligibilityCriteria":485,"healthyVolunteers":11,"sex":430,"minAge":486,"maxAge":487,"enrollmentInfo":488,"targetDuration":4,"studyType":47,"phases":490,"briefSummary":491,"conditions":492,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":37},"100641177","NCT07596498","Comparison of the Effectiveness and Learning Curve of Laparoscopic Pectopexy Versus Laparoscopic Sacrocolpopexy","Comparison of the Effectiveness and Learning Curve of Laparoscopic Pectopexy Versus Laparoscopic Sacrocolpopexy in Treatment of Apical Prolapse","Inclusion Criteria:\n\n* Patients diagnosed with uterine prolapse with POP-Q stage ≥ III.\n* Patients diagnosed with vault vaginal prolapse with POP-Q stage ≥ III.\n\nExclusion Criteria:\n\n* Patients who refuse to participate in the study.\n* Patients who have isolated anterior or posterior vaginal wall prolapse.\n* Women who are pregnant or lactating.\n* Patients with severe comorbidities, including: Serious heart, liver, kidney, or blood diseases or any condition preventing them from tolerating surgery.\n* Women with a desire to conceive.","40 Years","75 Years",{"count":489,"type":20},30,[49],"Pelvic organ prolapse, particularly apical prolapse, is a common condition among aging women, and laparoscopic sacrocolpopexy is considered the standard surgical treatment due to its high anatomical success. However, it poses technical challenges and risks related to sacral dissection.\n\nLaparoscopic pectopexy, a newer technique using the iliopectineal ligament for mesh fixation, offers a safer anatomical route with shorter operative time and fewer complications. The previous studies evaluate the sacrocolpopexy and pectopexy are all retrospective. This study is prospective randomized controlled study that adds Comparison on the success rate and learning curve of pectopexy versus sacrocolpopexy .",[493],"Apical Prolapse","2026-05-18",{"date":475,"type":29},{"date":497,"type":29},"2026-04-01",{"date":499,"type":20},"2026-10-10",{"name":35,"class":36},{"id":502,"slug":4,"hasResults":11,"nctId":503,"briefTitle":504,"officialTitle":504,"acronym":4,"eligibilityCriteria":505,"healthyVolunteers":11,"sex":506,"minAge":386,"maxAge":4,"enrollmentInfo":507,"targetDuration":4,"studyType":47,"phases":509,"briefSummary":510,"conditions":511,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":514,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":518,"locationsCount":4},"100638494","NCT07596537","The Effect of Detrusor Underactivity in Determining Outcomes After Transurethral Resection of the Prostate for Treatment of Benign Prostatic Hyperplasia","Inclusion Criteria:\n\n* Age: more than 50-year-old\n* Chronic urinary retention secondary to BPH\n* Prostate size Above 30 and less than 100gm\n\nExclusion Criteria:\n\n* Prostate size over 100 gm and less than 30 gm\n* Prostatic carcinoma\n* Urinary bladder carcinoma\n* Acute urinary retention\n* Urethral stricture.\n* Previous bladder, urethral or prostate surgery.\n* Acute urinary tract infection.\n* Neurogenic bladder","MALE",{"count":508,"type":20},90,[49],"The aim of this clinical trial is to evaluate the effect of detrusor underactivity on the functional and symptomatic outcomes following transurethral resection of the prostate (TURP) in benign prostatic hyperplasia patients presenting with chronic urinary retention.\n\nThe main questions it aims to answer are:\n\nWill they restore spontaneous voiding?\n\nThey will be divided into 2 comparative groups (each group 45 patients) based on detrusor contractility.\n\n* Group (A) consists of patients with normal detrusor (bladder contractility index more than 100).\n* Group (B) consists of patients with underactive detrusor (bladder contractility index less than 100).",[512,513],"Detrusor Underactivity","Transurethral Resection of the Prostate (TURP)",{"date":458,"type":29},{"date":516,"type":20},"2026-05-01",{"date":65,"type":20},{"name":35,"class":36},{"id":520,"slug":4,"hasResults":11,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":4,"eligibilityCriteria":524,"healthyVolunteers":11,"sex":16,"minAge":525,"maxAge":526,"enrollmentInfo":527,"targetDuration":4,"studyType":47,"phases":528,"briefSummary":529,"conditions":530,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":536,"leadSponsor":538,"locationsCount":37},"100640632","NCT07586592","Comparison of Age-Based Formula and Ultrasound-Guided Subglottic Diameter Measurement for Endotracheal Tube Sizing","Comparison of Age-Based Formula and Ultrasound-Guided Subglottic Diameter Measurement for Endotracheal Tube Sizing in Single Ventricle Patients","Inclusion Criteria:\n\n* Pediatric patients (3 months to 8 years)\n* Patients with single ventricle physiology\n* Scheduled for Glenn or Fontan surgery or cardiac catheterization\n* Patients with Glenn or Fontan shunt scheduled for surgery\n\nExclusion Criteria:\n\n* Refusal of legal guardians\n* Emergency surgery\n* Patients with tracheostomy tubes\n* Recent or active upper respiratory tract infection\n* Airway anomalies (e.g. Pierre Robin, Treacher Collins)\n* ICU stay due to complications other than that of airway","3 Months","8 Years",{"count":163,"type":20},[49],"To compare the accuracy of ultrasound-guided subglottic diameter measurement versus age-based formulas in determining the optimal endotracheal tube (ETT) size in pediatric patients with single ventricle physiology and reducing post-extubation complications.",[531],"Endotracheal Tube Wrongly Placed During Anesthetic Procedure","2026-05-08",{"date":534,"type":29},"2026-05-14",{"date":376,"type":29},{"date":537,"type":20},"2027-06-30",{"name":35,"class":36},{"id":540,"slug":4,"hasResults":11,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":4,"eligibilityCriteria":544,"healthyVolunteers":11,"sex":430,"minAge":44,"maxAge":248,"enrollmentInfo":545,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":547,"conditions":548,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":554,"leadSponsor":556,"locationsCount":4},"100640677","NCT07578246","\"Evaluating The Applicability of LASMAR Scoring in Predicting Surgical Outcomes Of Hysteroscopic Myomectomy\"","Evaluating The Applicability of LASMAR Scoring in Predicting Surgical Outcomes Of Hysteroscopic Myomectomy\"","Inclusion Criteria:\n\n* Women aged 18-45 years\n* Type 0,1,2 Fibroids according to Figo classification.\n* Symptomatic submucous fibroids: Symptoms include abnormal uterine bleeding, pelvic pain or pressure symptoms, infertility or recurrent pregnancy loss.\n* Fibroids size ≤ 5 cm in diameter\n* Confirmed diagnosis of leiomyoma by ultrasound .\n* Hemodynamically Stable Patients: Patients with no significant anemia.\n\nExclusion Criteria:\n\n* Contraindications to hysteroscopy (e.g., Pregnancy, pyometra, active infection)\n* Individuals with significant comorbidities (e.g., severe cardiovascular or respiratory diseases, bleeding diathesis).\n* Cases requiring concurrent procedures (e.g., Laparoscopic surgeries).\n* Fibroid Size\\>5 cm.",{"count":546,"type":20},88,"This study aims to evaluate the applicability of the LASMAR scoring system, derived from hysteroscopy, in predicting surgical outcomes in patients undergoing hysteroscopic myomectomy for submucous fibroids.",[549],"LAZMAR Scoring , Hysteroscopic Myomectomy","2026-05-05",{"date":552,"type":29},"2026-05-11",{"date":63,"type":20},{"date":555,"type":20},"2028-07-01",{"name":35,"class":36},""]